Table of Contents Author Guidelines Submit a Manuscript
Canadian Respiratory Journal
Volume 13, Suppl B, Pages 1B-9B
http://dx.doi.org/10.1155/2006/279435
Advisory Board Meeting Supplement

The Role of Omalizumab in the Treatment of Severe Allergic Asthma

Kenneth R Chapman,1 Andre Cartier,2 Jacques Hébert,3 R Andrew McIvor,4 and R Robert Schellenberg5

1Department of Medicine, Division of Respiratory Medicine, University of Toronto, Toronto, Ontario, Canada
2Department of Medicine, Division of Respiratory Medicine, University of Montreal, Montreal, Canada
3Allergy and Clinical Immunology, Centre hospitalier universitaire de Québec and Centre de recherché appliqué en allergie de Québec, Laval University, Laval, Quebec, Canada
4Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, Canada
5Department of Medicine, Division of Allergy and Immunology, University of British Columbia, Vancouver, British Columbia, Canada

Copyright © 2006 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Kenneth R Chapman, Andre Cartier, Jacques Hébert, R Andrew McIvor, and R Robert Schellenberg, “The Role of Omalizumab in the Treatment of Severe Allergic Asthma,” Canadian Respiratory Journal, vol. 13, no. Suppl B, pp. 1B-9B, 2006. https://doi.org/10.1155/2006/279435.